Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Chia Tai broadens its biparatopic breast cancer approach
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
ASCO 2025 – Astra seeks a new SERD paradigm
But camizestrant’s use could depend on uptake of monitoring – for now.
